» Articles » PMID: 12220382

Upregulated Survivin Expression in Activated T Lymphocytes Correlates with Disease Activity in Multiple Sclerosis

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2002 Sep 11
PMID 12220382
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Programmed cell death (apoptosis) is critical for the normal development and homeostasis of the immune system. There is emerging evidence that failure of apoptosis to eliminate potentially pathogenic, autoreactive T lymphocytes may be involved in the pathogenesis of multiple sclerosis (MS). This failure is related to multiple abnormalities of apoptosis-regulatory molecules that involve survivin, a recently described cell cycle-regulated anti-apoptosis protein. In this study, we investigated the relationship between survivin expression in peripheral T lymphocytes and clinical features of MS. We detected a significant over-expression of survivin in mitogen stimulated T lymphocytes from patients with active MS when compared with corresponding expression in patients with stable MS or those with inflammatory and non-inflammatory neurologic disorders. This over-expression of survivin in patients with active MS correlated with cellular resistance to apoptosis and with features of disease activity, such as disease duration and the number of enhanced lesions on cranial magnetic resonance imaging. There was no correlation between cellular survivin levels and the expression of other apoptosis-inhibitory proteins, such as Bcl-2 and Fas-associated death domain-like interleukin-1beta-converting enzyme inhibitory protein (FLIP). Our findings indicate that cellular over-expression of the novel anti-apoptosis protein survivin is a feature of clinically active MS.

Citing Articles

Single-Cell Analysis of CX3CR1+ Cells Reveals a Pathogenic Role for BIRC5+ Myeloid Proliferating Cells Driven by Staphylococcus aureus Leukotoxins.

Loredan D, Devlin J, Lacey K, Howard N, Chen Z, Zwack E J Immunol. 2023; 211(5):836-843.

PMID: 37466391 PMC: 10450158. DOI: 10.4049/jimmunol.2300166.


The Behaviour of Serum Survivin in Patients With Lupus Nephritis.

Lisboa R, de Oliveira F, Quaresma T, de Almeida R, Oliveira R, Junior P Biomark Insights. 2022; 17:11772719221131470.

PMID: 36311208 PMC: 9597205. DOI: 10.1177/11772719221131470.


A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis.

Barizzone N, Leone M, Pizzino A, Kockum I, Martinelli-Boneschi F, DAlfonso S J Pers Med. 2022; 12(9).

PMID: 36143216 PMC: 9501898. DOI: 10.3390/jpm12091430.


Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies.

Shomali N, Maashi M, Baradaran B, Daei Sorkhabi A, Sarkesh A, Mohammadi H Front Immunol. 2022; 13:839945.

PMID: 35309327 PMC: 8927965. DOI: 10.3389/fimmu.2022.839945.


The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model.

Zhang X, Ciesielski M, Fenstermaker R, Kaminski H, Kusner L J Immunol. 2020; 205(7):1743-1751.

PMID: 32839239 PMC: 7504892. DOI: 10.4049/jimmunol.2000482.